Lipid-polymer hybrid nanoparticle-mediated therapeutics delivery: advances and challenges

Rajendran J C Bose; Rramaswamy Ravikumar; Vengadeshprabu Karuppagounder; Devasier Bennet; Sabarinathan Rangasamy; Rajarajan A Thandavarayan

doi:10.1016/j.drudis.2017.05.015

Lipid-polymer hybrid nanoparticle-mediated therapeutics delivery: advances and challenges

Drug Discov Today. 2017 Aug;22(8):1258-1265. doi: 10.1016/j.drudis.2017.05.015. Epub 2017 Jun 8.

Authors

Rajendran J C Bose¹, Rramaswamy Ravikumar², Vengadeshprabu Karuppagounder³, Devasier Bennet⁴, Sabarinathan Rangasamy⁵, Rajarajan A Thandavarayan⁶

Affiliations

¹ School of Integrative Engineering, Chung-Ang University, Seoul, Republic of Korea. Electronic address: jaisangi14@cau.ac.kr.
² Department of Advanced Materials and Engineering, Hanseo University, Seosan-si, Republic of Korea.
³ Department of Clinical Pharmacology, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan.
⁴ Department of Mechanical Engineering, Texas Tech University, Lubbock, TX, USA.
⁵ Department of Chemistry, Central University of Tamil Nadu, Thiruvarur, India.
⁶ Department of Cardiovascular Sciences, Houston Methodist Research Institute, Houston, TX, USA. Electronic address: Atrajarajan@gmail.com.

PMID: 28600191
DOI: 10.1016/j.drudis.2017.05.015

Abstract

With rapid advances in nanomedicine, lipid-polymer hybrid nanoparticles (LPHNPs) have emerged as promising nanocarriers for several biomedical applications, including therapeutics delivery and biomedical imaging. Significant research has been dedicated to biomimetic or targeting functionalization, as well as controlled and image-guided drug-release capabilities. Despite this research, the clinical translation of LPHNP-mediated therapeutics delivery has progressed incrementally. In this review, we discuss the recent advances in and challenges to the development and application of LPHNPs, present examples to demonstrate the advantages of LPHNPs in therapeutics delivery and imaging applications, and discuss the translational obstacles to LPHNP technology.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Anti-Infective Agents / administration & dosage
Anti-Infective Agents / chemistry
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / chemistry
Cell Membrane / chemistry
Drug Delivery Systems*
Humans
Lipids* / administration & dosage
Lipids* / chemistry
Nanoparticles* / administration & dosage
Nanoparticles* / chemistry
Polymers* / administration & dosage
Polymers* / chemistry

Substances

Anti-Infective Agents
Antineoplastic Agents
Lipids
Polymers